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Abstract
Objectives:	This	 review	evaluated	 implant	 survival	 in	geriatric	patients	 (≥75	years)	
and/or the impact of systemic medical conditions.
Materials and Methods: Systematic literature searches were performed to identify 
studies reporting on geriatric subjects with dental implants and on implant patients 
who had any of the seven most common systematic conditions among geriatric pa‐
tients. Meta‐analyses were performed on the postloading implant survival rates. The 
impact of systemic medical conditions and their respective treatment was qualita‐
tively analyzed.
Results: A total of 6,893 studies were identified; of those, 60 studies were included. 
The	fixed‐effects	model	revealed	an	overall	implant	survival	of	97.3%	(95%	CI:	94.3,	
98.7;	studies	=	7)	and	96.1%	(95%	CI:	87.3,	98.9;	studies	=	3),	for	1	and	5	years,	re‐
spectively. In patients with cardiovascular disease, implant survival may be similar or 
higher compared to healthy patients. High implant survival rates were reported for 
patients with Parkinson’s disease or diabetes mellitus type II. In patients with cancer, 
implant survival is negatively affected, namely by radiotherapy. Patients with bone 
metastases receiving high‐dose antiresorptive therapy (ART) carry a high risk for 
complications after implant surgery. Implant survival was reported to be high in pa‐
tients receiving low‐dose ART for treatment of osteoporosis. No evidence was found 
on implant survival in patients with dementia, respiratory diseases, liver cirrhosis, or 
osteoarthritis.
Conclusions: Implant prostheses in geriatric subjects are a predictable treatment op‐
tion with a very high rate of implant survival. The functional and psychosocial bene‐
fits of such intervention should outweigh the associated risks to common medical 
conditions.
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1  | INTRODUC TION
Current demographic trends suggest that tooth loss now occurs in 
later life, and an increased number of patients will require tooth re‐
placements	at	an	advanced	age	(Hugoson	et	al.,	2005;	Stock,	Jurges,	
Shen,	Bozorgmehr	&	Listl,	2015).	In	Germany	and	Switzerland,	more	
than	90%	of	patients	aged	≥75	years	have	a	fixed	and/or	removable	
dental prosthesis, and this age group has an increasing number of 
implant restorations, compared to 20 years ago (Jordan & Micheelis, 
2016; Schneider, Zemp & Zitzmann, 2017). This trend was likewise 
reported in the Department of Oral Surgery and Stomatology at 
the University of Bern, School of Dental Medicine, where there is a 
marked increase since the year 2000 in implant surgeries in the age 
cohort	of	≥70	years	(Schimmel,	Müller,	Suter	&	Buser,	2017).	It	has	to	
be borne in mind that the prevalence of systemic medical conditions 
and frailty increase with age, and this may influence implant survival.
Today’s aged generation present new challenges in the field of 
implant dentistry. Old and very old patients, terms that are often 
used	 when	 referring	 to	 persons	 75	years	 or	 older,	 often	 present	
with functional dependency, multimorbidity, and frailty. This may 
or may not present a risk for implant placement, maintenance, and 
ultimately survival.
The world health report on aging published by the World Health 
Organization (WHO) lists the most common chronic conditions in 
elders: cardiovascular disease (CVD) (including ischemic heart dis‐
ease, stroke, and hypertensive heart disease), cancer, respiratory 
diseases (chronic obstructive pulmonary disease COPD, and lower 
respiratory infections), diabetes mellitus, cirrhosis of the liver, os‐
teoarthritis, and conditions that involve neurocognitive impairment 
(unipolar depression, Alzheimer’s disease, and other dementias) 
(WHO,	2015).
Additional risks may arise from the treatment of these medical 
conditions, including negative side effects. Polypharmacy as well 
as radiotherapy directed toward the salivary glands may cause 
symptoms of dry mouth. High‐dose bisphosphonates prescribed 
for the treatment of cancer with bone metastases may present 
a risk for necrosis of the jaw. Lower dose bisphosphonates are 
prescribed for the treatment of osteoporosis, although it is not 
listed among the seven most prevalent chronic systemic diseases 
in elders.
Any of these conditions or treatments might be considered by 
the patient or clinician as absolute or relative contraindication for im‐
plant surgery/therapy. Risks may be related to the surgical procedure 
itself, osseointegration, soft tissue response, as well as the long‐term 
survival of the implant (Bartold, Ivanovski & Darby, 2016; Bornstein, 
Cionca & Mombelli, 2009). Another pathway of failure may be more 
indirect, via neglected oral hygiene and improper implant mainte‐
nance. For example, patients with dementia are known to have lower 
motivation to perform regular and meticulous oral hygiene, in addi‐
tion to diminished cognitive and manual skills to perform the ade‐
quate procedures (Brändli, 2012). Reduced motor skills are also well 
documented for patients with rheumatoid arthritis (Lawrence et al., 
2008; Zhang et al., 2002) or stroke (Schimmel et al., 2011).
Implant success and survival are well documented for younger 
age	cohorts	 (Schimmel,	Srinivasan,	Herrmann	&	Müller,	2014),	but	
little is known about the effect of age on osseointegration and long‐
term	implant	survival	(Srinivasan,	Meyer,	Mombelli	&	Müller,	2016).	
In a comprehensive review of biological, clinical, and sociological 
considerations, Bartold et al. (2016) acknowledge the influence of 
physiological aging on wound healing. However, the complex pro‐
cess that leads to osseointegration of titanium implants as well as 
the accompanying inflammatory response has been mainly studied 
in animals (Bartold et al., 2016). Bornstein et al. reviewed and dis‐
cussed the available evidence in relation to medical conditions that 
may influence early and late implant failure (Bornstein, Cionca & 
Mombelli,	2015;	Bornstein	et	al.,	2009)	and	found	a	low	level	of	ev‐
idence that indicates absolute or relative contraindications for im‐
plant surgery. Furthermore, little is known about the reactions of the 
peri‐implant tissues to poor oral hygiene in geriatric patients (Holm‐
Pedersen,	Agerbaek	&	Theilade,	1975;	Meyer	et	al.,	2017).
In the scope of this review, geriatric patients were defined as pa‐
tients	with	an	age	of	75	years	and	above.	The	aim	of	this	systematic	
review was to screen and pool the available evidence to establish:
1. The dental implant survival rate in geriatric patients.
2. The potential impacts of the most common systemic medical con‐
ditions	(WHO,	2015)	and	their	treatments	on	implant	survival.
The focused question set for this systematic review was “In pa‐
tients undergoing dental implant therapy, what is the effect of ad‐
vanced	age	 (≥75	years)	 and/or	 common	 systemic	medical	 conditions	
on the implant survival, biological complication, and technical compli‐
cation rates?”
2  | MATERIAL AND METHODS
2.1 | Protocol and registration
This systematic review and meta‐analysis were conducted and re‐
ported	 according	 to	 the	 PRISMA	 guidelines	 (Moher	 et	al.,	 2015).	
The review protocol was registered with PROSPERO: International 
prospective register of systematic reviews (PROSPERO 2016: 
CRD42016049617).
2.2 | Eligibility criteria
All	human	studies	reporting	on	geriatric	individuals	(≥75	years)	with	
dental implants that satisfied the listed predefined inclusion criteria 
(Table 1) were included in the first part of this systematic review, 
which analyzed implant survival. Therefore, outcomes in healthy 
aged people were also sought.
For the second part of this search, no age limit was applied, as a 
preliminary screening of the literature did not identify any studies in 
relation to the most common medical conditions in the elderly (WHO, 
2015)	if	the	exclusion	criteria	included	those	aged	75	years	or	older.
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TA B L E  1   PICO focus question, criteria for inclusion, sources of information, search terms, search strategy, search filters, and search dates
Focus question
In patients undergoing dental implant therapy, what is the effect of advanced age (≥75 years) and/or common systemic 
medical conditions on the implant survival, biological complication, and technical complication, rates?
Criteria Inclusion criteria Dental implants placed in the completely and partially edentulous human participants
Implant‐supported fixed prostheses and implant‐supported/retained removable 
prostheses
Studies must specify the study design, number of participants, number of implants 
placed and failed, time of loading, and number of dropouts
Implant type: solid screw‐type implants
Participants must have been clinically examined during recall
Exclusion criteria Age	<75	years
One‐piece implants, Zygomatic implants, and pterygoid implants
Postloading follow‐up <12 months
Narrow diameter implants or mini dental implants (implants with diameter <3 mm)
Implants with turned or machined surface
Information sources Electronic databases MEDLINE (PubMed): https://www.ncbi.nlm.nih.gov/pubmed/; EMBASE: https://www.
embase.com/#search; and Central Register of Controlled Trials (CENTRAL) in the 
Cochrane Library: http://www.cochranelibrary.com.
Others Popular online internet search engines (e.g., Google and Yahoo), research community 
websites on the internet (https://www.researchgate.net/), reference cross‐checks, 
personal communications, and hand searches. Hand searches in dental journals were 
only performed for records not available electronically or without an electronic 
abstract
Search terms Population #1: (Elderly Adults) OR (Partially Edentulous) OR (Fully Edentulous) OR (Completely 
Edentulous) OR (Partially Edentulous Maxilla) OR (Fully Edentulous Maxilla) OR 
(Completely Edentulous Maxilla) OR (Partially Edentulous Mandible) OR (Fully 
Edentulous Mandible) OR (Completely Edentulous Mandible) OR (80 +  Aged) OR 
(75	+		Aged)	OR	(65	+		Aged)	OR	(Older	Patient)	OR	(Aged	Patients)
Intervention or exposure #2: (dental implantation, endosseous) OR (dental implants) OR (dental prosthesis, 
implant supported) OR (Overdentures) OR (Removable dental prostheses) OR (fixed 
dental prostheses) OR (dental implantation*) OR (dental implant) OR (implants) OR 
(implant supported fixed dental prostheses) OR (implant supported overdentures) OR 
(Removable dental prostheses*) OR (Overdentures) OR (Implant supported 
Overdentures) OR (Implant assisted Overdentures)
Comparison #3: (Cardiovascular disease) OR (ischemic heart disease) OR (stroke) OR (hypertensive 
heart disease) OR (cancer) OR (neoplasia) OR (COPD) OR (lower respiratory infections) 
OR (respiratory diseases) OR (Diabetes mellitus) OR (Cirrhosis) OR (Osteoarthritis) OR 
(neurocognitive disorder) OR (unipolar depression) OR (Alzheimer's disease) OR (other 
dementias) OR (Polypharmacy) OR (Hyposalivation) OR (Dry Mouth) OR (Multi 
Morbidity)
Outcome #4: (Survival) OR (survival rate) OR (survival analysis) OR (implant survival) OR (dental 
implant survival rate) OR (peri implantitis) OR (periimplant mucositis) OR (peri‐implant 
mucositis) OR (treatment failure) OR (prevalence) OR (mandibular implants failure rate) 
OR (maxillary implants failure rate) OR (success rate) OR (failure rate) OR (crestal bone 
loss) OR (periimplant bone loss) OR (bone loss) OR (periodontal conditions) OR 
(peri‐implant conditions) OR (implant success rates) OR (implant failure rates) OR 
(dental implant success rate) OR (dental implant failure rates) OR (biological 
complications)
Filters Language Not applied
Species Humans [MeSH]
Ages Aged [MeSH]
Journal categories Dental journals
(Continues)
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2.3 | Information sources
Three electronic databases were searched: MEDLINE (PubMed), 
EMBASE, and CENTRAL. Hand searches of dental journals were 
performed for records that were not accessible electronically or 
for those records without an electronic abstract available. Further 
searches resulting from reference cross‐checks were performed to 
identify studies that were not discovered online. Further attempts 
to maximize the pool of relevant studies and avoid any erroneous 
exclusion involved posting queries on research community web‐
sites (https://www.researchgate.net/) and, personal communica‐
tions sent to selected authors. The final update for all the electronic 
searches was performed on June 9, 2017.
2.4 | Search strategy
The search strategy was designed and set up by two experts in da‐
tabase searches (Table 1). An initial electronic search was performed 
by a single reviewer (MS). Then the search was repeated by a second 
reviewer (GMK) to confirm the number of discovered articles by the 
search strategy. The search terms employed were either medical 
subject headings (MeSH) terms or keywords classified under general 
(all fields) category. The search terms were then combined with an 
“OR,” and PICO categories were combined using “AND” to create a 
final logic search query (Supporting Information Table ).
2.5 | Study selection
All relevant studies were included in this review, if they fulfilled 
the inclusion criteria. A title and abstract screening was performed 
by two investigators independently (MS and GMK). A final list of 
studies was put forth for full‐text analysis and data extraction, only 
after a mutual agreement between the two investigators; disagree‐
ments, if any, were resolved by means of a consensus discussion. 
In cases of identified studies reporting on the same cohort at dif‐
ferent time points, only the most recent publication was included 
in the review.
2.6 | Data collection process
The investigators (MS and GMK) extracted data from the included 
studies independently and were reciprocally blinded. During data 
extraction, for any uncertainty involving the extracted variable, a 
consensus was always reached by both investigators before finaliz‐
ing the extracted data. In cases of significant doubts, corresponding 
authors were contacted for confirmation of the extracted informa‐
tion. The data items extracted from the included studies are speci‐
fied	in	Tables	2‒9.
2.7 | Missing data
Information was requested by email from the corresponding authors 
of included studies for missing or unclear data. In case of a nonre‐
sponse, email reminders were sent. A nonresponse from the cor‐
responding author ultimately resulted in the exclusion of the study 
from the review.
2.8 | Risk of bias and quality assessment of the 
included studies
The Cochrane collaboration’s tool and the Newcastle‐Ottawa 
scales were used for the assessment of the risk of bias and quality 
Focus question
In patients undergoing dental implant therapy, what is the effect of advanced age (≥75 years) and/or common systemic 
medical conditions on the implant survival, biological complication, and technical complication, rates?
Search queries run 
as performed in 
MEDLINE 
(PubMed)
Using search combination: #1 
AND #2 AND #3 AND #4 
AND Humans AND 
Aged = 1,207 (June 2017)†
†Detailed use of the various search terms and their combinations are presented in the 
Supporting Information Table 
Using search combination: #1 
AND #2 AND #4 AND 
Humans AND Aged = 1,210 
(June 2017)††
††Detailed use of the various search terms and their combinations are presented in the 
Supporting Information Table 
Specific Searches for systemic 
medical conditions and 
implants without any age 
filters (PubMed/
Medline) = 1,348 (June 2017)
1. Stroke AND Dental Implants AND Humans 2. Respiratory Diseases AND Dental 
Implants AND Humans 3. Cirrhosis AND Dental Implants AND Humans 4. 
Osteoarthritis	AND	Dental	Implants	AND	Humans	5.	Neuorcognitive	Disorders	AND	
Dental Implants AND Humans 6. Polypharmacy AND Dental Implants AND Humans 7. 
Hyposalivation OR Dry Mouth AND Dental Implants AND Humans 8. Multi morbidity 
AND Dental Implants AND Humans 9. Multimorbidity AND Dental Implants AND 
Humans 10. Cancer AND Dental Implants AND Humans 11. Cardiovascular Diseases 
AND Dental Implants and Humans
Search dates January	1980–26/05/2017 Final confirmatory online search was performed on 9 June 2017. No further online 
searches were performed after this date
TA B L E  1   (Continued)
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assessment of the included RCTs and prospective cohort/case–con‐
trol studies, respectively (Higgins & Green, 2011; Wells et al., 2014).
2.9 | Summary measures
2.9.1 | Primary outcome measure
The primary outcome measure in this review was calculated implant 
survival based on the reported number of implants placed and failed. 
This calculation provided the event rate in the first year postload‐
ing. Implants in dropout patients and in those patients not available 
for follow‐up were censored. Implant survival rate was assessed in 
the context of patient age and medical status. Implant failure has 
been defined as loss or removal of implant for any reason, and the 
timing of the failure has been described for the purpose of this re‐
view as either early, delayed, or late (ten Bruggenkate, Asikainen, 
Foitzik, Krekeler & Sutter, 1998). The loading protocols described in 
this review have been adopted as per the definitions of a previously 
published review (Schimmel et al., 2014).
2.9.2 | Secondary and tertiary outcome measures
Mean annual peri‐implant marginal bone loss (PI‐MBL), biological 
complications and any associated technical and/or mechanical com‐
plications were set as secondary and tertiary outcome parameters.
2.10 | Synthesis of results
Kappa (κ) statistics were calculated to confirm the interinvestigator 
agreement for the various extracted parameters. A meta‐analysis was 
performed on the included prospective studies for implant survival 
rates	at	1	and	5	years	postloading.	The	weighted	means	across	the	
studies were calculated using a fixed‐effects model. Heterogeneity 
across the included studies was assessed using the I‐squared statis‐
tics (I2 statistics). For the purpose of the meta‐analyses, case reports 
or case series reporting on less than 10 patients were excluded as 
the inclusion of individual participant data (IPD) would require a dif‐
ferent	statistical	approach	(Stewart	et	al.,	2015).	The	meta‐analysis	
was performed using a meta‐analysis software (CMA, version 3.0; 
Biostat,	Englewood,	NJ,	USA),	with	confidence	intervals	set	to	95%	
(95%	CI).
2.11 | Risk of publication bias and 
additional analyses
The risk of publication bias was explored across the included stud‐
ies using a funnel plot (Sterne & Egger, 2001). PI‐MBL, biological 
complications, technical/mechanical complications, and implant 
survival related to the medical status of the patients were reported 
descriptively.
3  | RESULTS
3.1 | Study selection
The search queries identified a total of 6,893 studies from the three 
electronic databases. After an initial sweep to eliminate duplicates 
and articles not relevant to the focus question followed by title and 
abstract screening, a combined total of 680 studies were selected 
for full‐text analysis. Initially, 46 relevant articles were shortlisted for 
inclusion in the review. After subsequent hand searches, reference 
cross‐checks, and information from other sources and authors, an 
additional 16 articles were identified. Four authors provided novel 
subanalyses from their published cohorts to report only on patients 
aged	75	years	or	 older	 (Antoun,	Karouni,	Abitbol,	 Zouiten	&	 Jemt,	
2017; Bressan & Lops, 2014; Hoeksema, Visser, Raghoebar, Vissink 
& Meijer, 2016; Ormianer & Palti, 2006). A final total of 62 relevant 
articles were included in the review for data extraction. The flow of 
the entire search and the article identification process is shown in 
Figure 1.
TA B L E  3   Peri‐implant marginal bone loss (PI‐MBL), technical, and biological complications reported by the included RCTs and 
prospective studies
Study (first 
author)
Publication 
year PI‐MBL in millimeters
Technical/mechanical 
complications (n)
Biological 
complications (n)
Calculated annual bone 
loss in millimeters
Becker 2016 0.1 (annual) n.r. n.r. 0.1
Bressan 2014 0.4 (over 2 years) n = 0 n = 2 Peri‐implant 
mucositis
0.2
Cakarer 2011 n.r. n = 2 1 Prosthesis fracture 1 
Clips activation
n = 1 Mucosal 
enlargement 
around ball 
attachment
n.a.
de Carvalho 2013 1.0	(over	5	years)	 n = 0 n = 0 0.20
Hoeksema 2015 0.51	(at	1	year) n = 0 n = 0 0.51	(first	year	postloading)
Maniewicz 2017 0.17 (annual) n.r. n.r. 0.17
Müller 2015 0.61	(over	5	years) n.r. n.r. 0.12
Note. n: number of events; n.r.: not reported; n.a.: not applicable; RCTs: randomized controlled trials.
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3.2 | Study characteristics
3.2.1 | Studies included for meta‐analysis
From the included final list of 62 publications, seven prospective studies 
reported	exclusively	on	geriatric	cohorts	aged	≥75	years	(Becker,	Hujoel,	
Becker & Wohrle, 2016; Bressan & Lops, 2014; Cakarer, Can, Yaltirik & 
Keskin, 2011; de Carvalho, de Carvalho & Consani, 2013; Hoeksema 
et	al.,	2016;	Maniewicz	Wins	et	al.,	2017;	Müller	et	al.,	2015)	(Table	2).	
Among	these,	there	was	one	RCT	(Müller	et	al.,	2015),	one	prospective	
controlled clinical trial (Hoeksema et al., 2016), and five prospective 
case series (Becker et al., 2016; Bressan & Lops, 2014; Cakarer et al., 
2011; de Carvalho et al., 2013; Maniewicz Wins et al., 2017). These 
three prospective studies were included in the meta‐analysis for 1‐year 
postloading	implant	survival	in	a	geriatric	population,	aged	75	years	or	
older; while six of these studies also provided information for inclu‐
sion	in	the	meta‐analysis	for	the	5	year	postloading	implant	survival	(de	
Carvalho	et	al.,	2013;	Maniewicz	Wins	et	al.,	2017;	Müller	et	al.,	2015).
3.2.2 | Studies included for descriptive analysis
The	remaining	53	studies	reported	on	cohorts	with	the	most	com‐
mon systemic medical conditions or their respective treatment and 
their effect on implant survival. The analyses included both, the in‐
dividual medical conditions and their treatment effects. Although 
these studies report on all‐age cohorts, they were still included in 
this review because no studies were identified for cohorts aged 
75	years	and	over.
3.3 | Synthesis of results
3.3.1 | Inter‐investigator agreement
The calculated κ‐range was 0.637–1.000, and 0.800–1.000, for the dif‐
ferent stages of the search process, and the various parameters of the 
extracted data, respectively, which is defined as good to almost perfect 
reliability between the two independent investigators (MS and GMK).
3.3.2 | Meta‐analysis of the included studies: 
Implant survival in geriatric subjects
A meta‐analysis was performed for the postloading implant survival 
rates calculated for observation periods at 1 year (Becker et al., 
2016; Bressan & Lops, 2014; Cakarer et al., 2011; de Carvalho et al., 
2013;	Hoeksema	et	al.,	2016;	Maniewicz	et	al.,	2017;	Müller	et	al.,	
2015).	The	fixed‐effects	model	revealed	an	overall	1‐year	postload‐
ing	 implant	survival	of	96.7%	(95%	CI:	94.3,	98.7;	 I2 = 0.00%; n = 7 
studies;	Figure	2).	Three	studies	provided	 information	 for	a	5‐year	
meta‐analysis and revealed an overall postloading implant survival 
of	96.1%	(95%	CI:	87.3,	98.9;	I2 = 0.00%, Figure 3) (de Carvalho et al., 
2013;	Maniewicz	et	al.,	2017;	Müller	et	al.,	2015).	According	to	the	
funnel plot analysis, a possible publication bias across the studies 
included in the meta‐analysis was explored and ruled out (Figure 4).T
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3.3.3 | Calculated annual peri‐implant bone loss
The calculated annual peri‐implant bone loss was reported to range 
from	0.1	mm	 annually	 (Becker	 et	al.,	 2016)	 to	 0.51	mm	during	 the	
first year postloading (Hoeksema et al., 2016) for geriatric subjects 
aged	≥75	years	(Table	3).
3.4 | Medical conditions and their treatment
3.4.1 | Cardiovascular disease (including ischemic 
heart disease, stroke, hypertensive heart disease)
Implant survival in relation to CVD or associated treatment was 
reported in two studies (Table 4). In particular, Wu et al. (2016) re‐
ported a higher survival rate of implants in patients treated with an‐
tihypertensive therapy. In contrast, Alsaadi, Quirynen, Komarek and 
van Steenberghe (2008) did not find an influence of hypertensive 
heart disease on implant survival.
3.4.2 | Cancer
Radiotherapy
The effects of radiotherapy for the treatment of cancer in the head 
and neck region on implant survival were included in this system‐
atic review. Seventeen studies were identified which met the inclu‐
sion	and	exclusion	criteria	(Table	5)	(Arcuri,	Fridrich,	Funk,	Tabor	&	
LaVelle, 1997; Bodard et al., 2011; Buddula et al., 2012; Cuesta‐Gil 
et al., 2009; Eckert, Desjardins, Keller & Tolman, 1996; Ernst et al., 
2016; Fenlon et al., 2012; Gander, Studer, Studer, Gratz & Bredell, 
2014; Heberer, Kilic, Hossamo, Raguse & Nelson, 2011; Hessling 
et	al.,	 2015;	 Korfage	 et	al.,	 2014;	 Linsen,	 Martini	 &	 Stark,	 2012;	
Mancha de la Plata et al., 2012; Mericske‐Stern, Perren & Raveh, 
1999;	 Pompa	 et	al.,	 2015;	 Sammartino,	 Marenzi,	 Cioffi,	 Tete	 &	
Mortellaro, 2011). Most of the studies reported on implants placed 
after radiotherapy (Arcuri et al., 1997; Bodard et al., 2011; Ernst 
et al., 2016; Gander et al., 2014; Heberer et al., 2011; Hessling et al., 
2015;	Korfage	et	al.,	2014;	Linsen	et	al.,	2012;	Mancha	de	 la	Plata	
et	al.,	2012;	Pompa	et	al.,	2015;	Sammartino	et	al.,	2011).	Only	two	
studies also included patients with implants placed prior to radio‐
therapy	(Hessling	et	al.,	2015;	Mericske‐Stern	et	al.,	1999).
Survival	 rates	 were	 reported	 to	 range	 between	 57.1%	 for	 im‐
mediately placed implants into vascularized grafts with subsequent 
radiotherapy (Fenlon et al., 2012) and 97.9% (Heberer et al., 2011).
Most investigators reported a time lapse between radiotherapy 
and implant placement of more than 12 months; however, some uti‐
lized a shorter delay (Ernst et al., 2016; Heberer et al., 2011; Korfage 
et al., 2014; Sammartino et al., 2011).
Antiresorptive therapy
Patients with bone metastases, including breast and prostate cancer 
or those suffering from multiple myeloma often receive high‐dose in‐
travenous antiresorptive therapy (ART) that may be associated with 
medication‐related osteonecrosis of the jaw (MRONJ) (Jacobsen 
et al., 2013; Kwon et al., 2014). A recent review supports the state‐
ment that dental implant treatment is contraindicated in these pa‐
tients because of the greatly increased risk of MRONJ (Lazarovici 
et al., 2010).
In a different context, ART is a very common treatment for 
osteoporosis. The current systematic search identified 14 articles 
that provided information about the implant survival in patients 
treated with ART for osteoporosis and osteopenia (Table 6) (Bell 
& Bell, 2008; Fugazzotto, Lightfoot, Jaffin & Kumar, 2007; Goss, 
Bartold, Sambrook & Hawker, 2010; Grant, Amenedo, Freeman & 
Kraut, 2008; Griffiths, 2012; Jacobsen et al., 2013; Koka, Babu & 
Norell, 2010; Kwon et al., 2014; Lopez‐Cedrun et al., 2013; Martin 
et al., 2010; Memon, Weltman & Katancik, 2012; Shabestari et al., 
2010;	 Siebert,	 Jurkovic,	 Statelova	 &	 Strecha,	 2015;	 Tallarico,	
Canullo, Xhanari & Meloni, 2016; Zahid, Wang & Cohen, 2011). 
Another two articles reported on mixed indications, including ma‐
lignancies (Jacobsen et al., 2013; Kwon et al., 2014). In studies of 
osteoporotic patients managed with ART, reported implant survival 
rates were predominately high. The prevalence of MRONJ in these 
patient cohorts was rarely specified (Fugazzotto et al., 2007; Goss 
et al., 2010; Griffiths, 2012; Shabestari et al., 2010; Siebert et al., 
2015;	Zahid	et	al.,	2011).
Hyposalivation
The effect of hyposalivation on implant survival was only reported 
for patients with Sjögren’s syndrome, rather than in cancer pa‐
tients with radiotherapy (Table 7) (de Mendonca Invernici et al., 
2014; Korfage et al., 2016; Oczakir, Balmer & Mericske‐Stern, 
2005;	 Spinato,	 Soardi	 &	 Zane,	 2010;	 Weinlander,	 Krennmair	 &	
Piehslinger, 2010). Survival rates were reported to be 100% (de 
Mendonca	Invernici	et	al.,	2014;	Oczakir	et	al.,	2005;	Spinato	et	al.,	
2010; Weinlander et al., 2010), with the exception of a recent com‐
parative study, which reported a small number of early implant fail‐
ures (Korfage et al., 2016).
3.4.3 | Respiratory diseases (chronic obstructive 
pulmonary disease COPD and lower respiratory 
infections)
No articles reporting on implant survival in patients with COPD or 
other respiratory diseases were identified in the search.
3.4.4 | Diabetes mellitus
A number of recent prospective cohort studies reported on the 
survival of implants in adult patients with diabetes mellitus, mainly 
Type 2 (Table 8) (Aguilar‐Salvatierra et al., 2016; Alsaadi et al., 2008; 
Dowell,	 Oates	 &	 Robinson,	 2007;	 Erdogan	 et	al.,	 2015;	 Eskow	 &	
Oates, 2017; Oates et al., 2014; Peled, Ardekian, Tagger‐Green, 
Gutmacher & Machtei, 2003). Calculated survival rates were re‐
ported to range from 86.3% (24‐month observation period) (Aguilar‐
Salvatierra et al., 2016) to 100% (12 months) (Oates et al., 2014). 
Poor control (HbA1c	≥	8.0%)	may	have	an	influence.
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TA B L E  5   Studies reporting on implant survival in patients with cancer treated with radiotherapy in the neck and head region [In PDF  
format, this table is best viewed in two‐page mode]
Study (first author)
Publication 
year
Study 
design
Radiation 
dose (Gy) Time of placement
Observation period 
(in months)
Number of  
patients (n)
Mean age (in 
years)
Total number of implants 
placed in the study period (n)
Total number of implants 
failed in the study period (n)
Number of implants 
survived (n)
Calculated implant 
survival rate (SR%)
Time of failure 
(months)
Arcuri 1997 Retro 56–65 >12 months post‐Ra 12–60 4 51 18 1 17 94.4 n.r.
Bodard 2011 Retro n.r. n.r. 27.5 23 n.r. 75 n.r. n.r. 80.0 n.r.
Buddula 2012 Retro 50.2–67.5 41 months post‐Ra (mean) 60.0 48 60.2 271 33 238 87.8 n.r.
Cuesta‐Gil 2009 Retro 50–60 pre‐Ra or >12 months post‐Ra 6–108 79 52 395 75 320 81.0 n.r.
Eckert 1996 Retro 20–65 post‐Ra n.r. 21 n.r. 111 9 102 91.9 n.r.
Ernst 2016 Retro 55–72 6 months post‐Ra 52.9 17 n.r. 88 3 85 96.6 2 in 12, 1 in 48
Fenlon 2012 CS 65 pre‐Ra n.r. 12 n.r. 35 15 20 57.1 <6
Gander 2014 Retro 56–76 42 months post‐Ra (mean) 20.0 21 64.15 84 12 72 85.7 2–18
Heberer 2011 Pros ≤72 >6 months post‐Ra 14.4 20 61.1 97 2 95 97.94 Early
Hessling 2015 Retro 40 pre‐Ra <60 21 55 95 2 93 97.89 2 in 24
Hessling 2015 Retro 61–66 post‐Ra <60 28 55 128 6 122 95.3 1	in	24,	5	in	60
Korfage 2014 Follow‐up n.r. >6 months post‐Ra 45.6 100 55.7 318 27 291 91.5 n.r.
Linsen 2012 Retro 36–60 mean: 41.0 months post‐Ra 60.0 34 n.r. 127 8 119 93.7 n.r.
Mancha de la Plata 2012 Retro 50–70 33.4 months post‐Ra 23 pat pre‐Ra 6–96	(mean	45) 30 55.5 225 23 203 90.2 n.r.
Mericske‐Stern 1999 Follow‐up 50–74 pre‐Ra 12–84 4 n.r. 17 2 15 88.2 n.r.
Pompa 2015 Retro ≤50 12 months post‐Ra Mean 22.9 12 51	 51 12 39 76.5 n.r.
Sammartino 2011 Pros 50 Mean 9.4 months post‐Ra <36.0 77 55.8 172 20 152 88.4 <12 months
Note. n.r.: not reported; n: number; Retro: retrospective study; CS: case series; Pros: Prospective study; post‐Ra: implant postradiotherapy; 
pre‐Ra: placement preradiotherapy; Early: before implant loading; Late: after implant loading; SR: calculated survival rate.
TA B L E  6   Studies reporting on implant survival in patients treated with antiresorptive drugs because of osteoporosis and/or cancer  
treatment [In PDF format, this table is best viewed in two‐page mode]
Study (publication year) Study design Route Indication for ART
Duration of ART before/no onset of  
MRONJ (months)
Number of patients 
(n)
Mean age in 
years
Follow‐up period 
(months)
Number of implants 
placed (n)
Number of implants 
failed (n) Time of failure (months) SR (%)
Bell (2008) Retro Oral n.r. No onset (ART 6‐132) 42 n.r. 7–89 100 5 Multiple time points 95
Fugazzotto (2007) Retro Oral n.r. No onset (ART: mean: 39.6) 61 51–83 12–24 169 0 n.r. 100
Goss (2010) CS Oral Osteoporosis MRONJ in 10 weeks to 120 7 65.7 n.r. 19 9 n.r. 52.6
Grant (2008) CS Oral Osteoporosis No onset (ART: mean: 38) 115 67.4 <96 468 2 Early 99.6
Griffiths (2012) RCT Oral n.r. None with ART 10 62 <18 14 0 n.r. 100
Jacobsen (2013) CS Oral + IV Malignancy (n = 9)/
osteoporosis (n	=	5)
MRONJ	in	38–50	months	after	implant	 
placement 
12 n.r. 60 23 n.r. 20.9
Koka (2010) Retro Oral Osteoporosis/Osteopenia No onset (ART 72) 55 71 n.r. 121 1 n.r. 99.2
Kwon (2014) CS Oral + IV Osteoporosis/multiple 
myeloma
MRONJ in 3‐82 19 67.3 >60 n.r. 18 n.r.
Lopéz‐Cedrún (2013) Retro Oral Osteoporosis/Polymyalgia/
rheumatic
MRONJ in 6‐120 9 66 <36 57 10 1–96.0 82.5
Martin (2010) Retro Oral Osteoporosis No onset 589 70.2 n.r. 44 in 16 patients 26 in 16 patients 1–132 40.9
Memon (2012) Retro Oral Osteoporosis No onset (ART: 0–36+) 100 66 n.r. 153 10 Early 93.5
Shabestari (2010) Retro Oral Osteoporosis No onset (ART before placement: 0–60; ART  
after placement: 0–36)
21 53 <96 46 0 n.r. 100
Siebert	(2015) Pros IV Osteoporosis No onset (ART: mean: 36) 12 54+ 12 60 0 n.r. 100
Tallarico	(2015) Pros Oral Osteoporosis No onset (ART: mean: 36) 32 64.4 36–72 98 1 Early 98.98
Zahid (2011) Retro Oral Osteoporosis No onset (ART 18‐192) 26 56 2–78 51 3 Early 94.12
Note. n.r.: not reported; Retro: retrospective study; RCT: randomized clinical trial; CS: case series; Pros: prospective study; ART: antiresorptive 
therapy; Route: route of administration; IV: intravenous administration; Early: before implant loading; Late: after implant loading; SR: calculated 
survival rate.
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TA B L E  5   Studies reporting on implant survival in patients with cancer treated with radiotherapy in the neck and head region [In PDF  
format, this table is best viewed in two‐page mode]
Study (first author)
Publication 
year
Study 
design
Radiation 
dose (Gy) Time of placement
Observation period 
(in months)
Number of  
patients (n)
Mean age (in 
years)
Total number of implants 
placed in the study period (n)
Total number of implants 
failed in the study period (n)
Number of implants 
survived (n)
Calculated implant 
survival rate (SR%)
Time of failure 
(months)
Arcuri 1997 Retro 56–65 >12 months post‐Ra 12–60 4 51 18 1 17 94.4 n.r.
Bodard 2011 Retro n.r. n.r. 27.5 23 n.r. 75 n.r. n.r. 80.0 n.r.
Buddula 2012 Retro 50.2–67.5 41 months post‐Ra (mean) 60.0 48 60.2 271 33 238 87.8 n.r.
Cuesta‐Gil 2009 Retro 50–60 pre‐Ra or >12 months post‐Ra 6–108 79 52 395 75 320 81.0 n.r.
Eckert 1996 Retro 20–65 post‐Ra n.r. 21 n.r. 111 9 102 91.9 n.r.
Ernst 2016 Retro 55–72 6 months post‐Ra 52.9 17 n.r. 88 3 85 96.6 2 in 12, 1 in 48
Fenlon 2012 CS 65 pre‐Ra n.r. 12 n.r. 35 15 20 57.1 <6
Gander 2014 Retro 56–76 42 months post‐Ra (mean) 20.0 21 64.15 84 12 72 85.7 2–18
Heberer 2011 Pros ≤72 >6 months post‐Ra 14.4 20 61.1 97 2 95 97.94 Early
Hessling 2015 Retro 40 pre‐Ra <60 21 55 95 2 93 97.89 2 in 24
Hessling 2015 Retro 61–66 post‐Ra <60 28 55 128 6 122 95.3 1	in	24,	5	in	60
Korfage 2014 Follow‐up n.r. >6 months post‐Ra 45.6 100 55.7 318 27 291 91.5 n.r.
Linsen 2012 Retro 36–60 mean: 41.0 months post‐Ra 60.0 34 n.r. 127 8 119 93.7 n.r.
Mancha de la Plata 2012 Retro 50–70 33.4 months post‐Ra 23 pat pre‐Ra 6–96	(mean	45) 30 55.5 225 23 203 90.2 n.r.
Mericske‐Stern 1999 Follow‐up 50–74 pre‐Ra 12–84 4 n.r. 17 2 15 88.2 n.r.
Pompa 2015 Retro ≤50 12 months post‐Ra Mean 22.9 12 51	 51 12 39 76.5 n.r.
Sammartino 2011 Pros 50 Mean 9.4 months post‐Ra <36.0 77 55.8 172 20 152 88.4 <12 months
Note. n.r.: not reported; n: number; Retro: retrospective study; CS: case series; Pros: Prospective study; post‐Ra: implant postradiotherapy; 
pre‐Ra: placement preradiotherapy; Early: before implant loading; Late: after implant loading; SR: calculated survival rate.
TA B L E  5   (additional columns)
TA B L E  6   Studies reporting on implant survival in patients treated with antiresorptive drugs because of osteoporosis and/or cancer  
treatment [In PDF format, this table is best viewed in two‐page mode]
Study (publication year) Study design Route Indication for ART
Duration of ART before/no onset of  
MRONJ (months)
Number of patients 
(n)
Mean age in 
years
Follow‐up period 
(months)
Number of implants 
placed (n)
Number of implants 
failed (n) Time of failure (months) SR (%)
Bell (2008) Retro Oral n.r. No onset (ART 6‐132) 42 n.r. 7–89 100 5 Multiple time points 95
Fugazzotto (2007) Retro Oral n.r. No onset (ART: mean: 39.6) 61 51–83 12–24 169 0 n.r. 100
Goss (2010) CS Oral Osteoporosis MRONJ in 10 weeks to 120 7 65.7 n.r. 19 9 n.r. 52.6
Grant (2008) CS Oral Osteoporosis No onset (ART: mean: 38) 115 67.4 <96 468 2 Early 99.6
Griffiths (2012) RCT Oral n.r. None with ART 10 62 <18 14 0 n.r. 100
Jacobsen (2013) CS Oral + IV Malignancy (n = 9)/
osteoporosis (n	=	5)
MRONJ	in	38–50	months	after	implant	 
placement 
12 n.r. 60 23 n.r. 20.9
Koka (2010) Retro Oral Osteoporosis/Osteopenia No onset (ART 72) 55 71 n.r. 121 1 n.r. 99.2
Kwon (2014) CS Oral + IV Osteoporosis/multiple 
myeloma
MRONJ in 3‐82 19 67.3 >60 n.r. 18 n.r.
Lopéz‐Cedrún (2013) Retro Oral Osteoporosis/Polymyalgia/
rheumatic
MRONJ in 6‐120 9 66 <36 57 10 1–96.0 82.5
Martin (2010) Retro Oral Osteoporosis No onset 589 70.2 n.r. 44 in 16 patients 26 in 16 patients 1–132 40.9
Memon (2012) Retro Oral Osteoporosis No onset (ART: 0–36+) 100 66 n.r. 153 10 Early 93.5
Shabestari (2010) Retro Oral Osteoporosis No onset (ART before placement: 0–60; ART  
after placement: 0–36)
21 53 <96 46 0 n.r. 100
Siebert	(2015) Pros IV Osteoporosis No onset (ART: mean: 36) 12 54+ 12 60 0 n.r. 100
Tallarico	(2015) Pros Oral Osteoporosis No onset (ART: mean: 36) 32 64.4 36–72 98 1 Early 98.98
Zahid (2011) Retro Oral Osteoporosis No onset (ART 18‐192) 26 56 2–78 51 3 Early 94.12
Note. n.r.: not reported; Retro: retrospective study; RCT: randomized clinical trial; CS: case series; Pros: prospective study; ART: antiresorptive 
therapy; Route: route of administration; IV: intravenous administration; Early: before implant loading; Late: after implant loading; SR: calculated 
survival rate.
TA B L E  6   (additional columns)
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3.4.5 | Cirrhosis of the liver
No articles reporting on implant survival in patients with cirrhosis of 
the liver were identified by the search criteria.
3.4.6 | Osteoarthritis
No articles reporting on implant survival in patients with osteoar‐
thritis were discovered by the search criteria.
3.4.7 | Neurocognitive impairment (unipolar 
depression, Alzheimer's disease and other 
dementias, and Parkinson's disease)
The search revealed no data regarding implant survival in patients 
with Alzheimer’s disease or other forms of dementia. Studies ad‐
dressing other forms of neurocognitive impairment and implant 
survival are listed in Table 9 (Chu, Deng, Siu & Chow, 2004; Deniz, 
Kokat & Noyan, 2011; Ekfeldt, Zellmer & Carlsson, 2013; Heckmann, 
Heckmann & Weber, 2000; Jackowski et al., 2001; Packer, Nikitin, 
Coward, Davis & Fiske, 2009; Wu et al., 2014). One study reported 
higher implant failure rates in patients taking selective serotonin 
reuptake inhibitors for depression compared to nonusers of SSRIs 
(Wu et al., 2014). Case reports and case series with a limited num‐
ber of participants reported on patients with Parkinson’s disease 
with calculated survival rates ranging between 82.1% (Packer et al., 
2009) and 100% (Chu et al., 2004; Heckmann et al., 2000).
4  | DISCUSSION
4.1 | Principal findings
This review identified high implant survival rates in geriatric patients 
aged	75	years	and	older.	The	1	and	5‐year	implant	survival	rates	are	
similar to those reported in younger cohorts (Al‐Nawas et al., 2012; 
Müller	et	al.,	2015),	 irrespective	of	 the	clinical	 indications	or	 load‐
ing protocol (Benic, Mir‐Mari & Hammerle, 2014; Papaspyridakos, 
Chen, Chuang & Weber, 2014; Schimmel et al., 2014; Schrott, Riggi‐
Heiniger, Maruo & Gallucci, 2014). It is important to note that the 
1‐year survival rates reflect implants failing to osseointegrate, and 
therefore, it could be suggested that advanced age does not seem to 
negatively affect osseointegration.
Clinical decision‐making should take into consideration the oral 
and systemic health of every patient with comorbidities in form of 
an individualized risk assessment comprising a close collaboration 
with medical specialists and the family doctor. Implant placement in 
oncologic patients must be performed with caution and, if at all, an 
adequate refractory period postradiotherapy (>12 months) should 
be respected. Individualized treatment planning including assess‐
ment of radiation protocol must be carefully tailored and should be 
performed in a specialist setting; however, the risk of osteonecrosis 
cannot be ruled out. Implant placement in patients receiving high‐
dose ART is contraindicated.T
A
B
L
E
 7
 
St
ud
ie
s 
re
po
rt
in
g 
on
 im
pl
an
t s
ur
vi
va
l i
n 
pa
tie
nt
s 
w
ith
 h
yp
os
al
iv
at
io
n
St
ud
y 
(f
ir
st
 
au
th
or
)
P
ub
lic
at
io
n 
ye
ar
St
ud
y 
de
si
gn
In
ve
st
ig
at
ed
 
co
nd
iti
on
O
bs
er
va
tio
n 
pe
ri
od
 (i
n 
m
on
th
s)
N
um
be
r o
f 
pa
ti
en
ts
 (n
)
M
ea
n 
ag
e 
in
 y
ea
rs
To
ta
l n
um
be
r o
f 
im
pl
an
ts
 p
la
ce
d 
in
 th
e 
st
ud
y 
pe
ri
od
 (n
)
To
ta
l n
um
be
r o
f 
im
pl
an
ts
 fa
ile
d 
in
 
th
e 
st
ud
y 
pe
rio
d 
(n
)
N
um
be
r o
f 
im
pl
an
ts
 
su
rv
iv
ed
 (n
)
C
al
cu
la
te
d 
im
pl
an
t 
su
rv
iv
al
 ra
te
 
(S
R
%
)
T
im
e 
of
 
fa
ilu
re
Ko
rf
ag
ea
20
16
Re
tr
o
Sj
ög
re
n'
s
45
.6
50
	(♀
 =
 4
6,
 
♂ 
= 
4)
67
14
0
4
13
6
97
.1
Ea
rly
Re
tr
o
H
ea
lth
y 
co
nt
ro
ls
60
.0
50
	(♀
 =
 4
6,
 
♂ 
= 
4)
66
12
5
0
12
5
10
0
n.
a.
de
 M
en
do
nç
a 
20
14
C
as
e 
re
po
rt
Sj
ög
re
n'
s
72
1
58
2
0
2
10
0
n.
a.
O
cz
ak
ir
20
05
C
as
e 
se
rie
s
Sj
ög
re
n'
s
24
–6
0
2
63
.5
12
0
12
10
0
n.
a.
Sp
in
at
o
20
10
C
as
e 
re
po
rt
Sj
ög
re
n'
s
12
1
62
6
0
6
10
0
n.
a.
W
ei
nl
an
de
r
20
10
Re
tr
o
Sj
ög
re
n'
s 
+ 
R
A
57
.7
4
55
.6
21
0
21
10
0
n.
a.
N
ot
e.
 ♀
: W
om
en
; ♂
: M
en
; n
.r.
: n
ot
 re
po
rt
ed
; R
et
ro
: r
et
ro
sp
ec
tiv
e 
st
ud
y;
 E
ar
ly
: b
ef
or
e 
im
pl
an
t l
oa
di
ng
; L
at
e:
 a
ft
er
 im
pl
an
t l
oa
di
ng
; S
R:
 c
al
cu
la
te
d 
su
rv
iv
al
 ra
te
; n
.a
.: 
no
t a
pp
lic
ab
le
.
a D
iff
er
en
t s
tu
dy
 g
ro
up
s 
w
ith
in
 th
e 
sa
m
e 
st
ud
y 
re
po
rt
ed
 in
 s
ep
ar
at
e 
ro
w
s.
322  |     SCHIMMEL Et aL.
T
A
B
L
E
 8
 
St
ud
ie
s 
re
po
rt
in
g 
on
 im
pl
an
t s
ur
vi
va
l i
n 
pa
tie
nt
s 
w
ith
 d
ia
be
te
s 
m
el
lit
us
St
ud
y 
(f
ir
st
 
au
th
or
)
P
ub
lic
at
io
n 
ye
ar
St
ud
y 
de
si
gn
In
ve
st
ig
at
ed
 
co
nd
iti
on
 re
la
te
d 
to
 
di
ab
et
es
O
bs
er
va
tio
n 
pe
rio
d 
 
(in
 m
on
th
s)
N
um
be
r o
f 
pa
ti
en
ts
 (n
)
M
ea
n 
ag
e 
 
(in
 y
ea
rs
)
To
ta
l n
um
be
r o
f 
im
pl
an
ts
 p
la
ce
d 
in
 th
e 
st
ud
y 
pe
ri
od
 (n
)
To
ta
l n
um
be
r o
f 
im
pl
an
ts
 fa
ile
d 
in
 
th
e 
st
ud
y 
pe
rio
d 
(n
)
N
um
be
r o
f 
im
pl
an
ts
 
su
rv
iv
ed
 
(t
ot
al
)
C
al
cu
la
te
d 
im
pl
an
t 
su
rv
iv
al
 ra
te
 
(S
R
%
)
T
im
e 
of
 
fa
ilu
re
A
gu
ila
r‐
Sa
lv
at
ie
rr
aa
20
16
Pr
os
H
bA
1c
	≤
	6
,	T
yp
e	
2
24
33
59
33
0
33
10
0
n.
a.
H
bA
1c
 =
 6
.1
–8
.0
, 
Ty
pe
 2
24
30
57
30
1
29
96
.6
La
te
H
bA
1c
 =
 8
.0
–1
0,
 
Ty
pe
 2
24
22
61
22
3
19
86
.3
La
te
A
ls
aa
di
a
20
08
C
S
Ty
pe
 1
 
n.
r.
n.
r.
56
.2
1
1
0
0
Ea
rly
Ty
pe
 2
 
n.
r.
n.
r.
56
.2
24
1
23
95
.8
3
n.
r.
D
ow
el
la
20
07
C
oh
or
t (
Pr
os
)
Ty
pe
 2
4
25
51
–8
1
38
0
38
10
0
n.
a.
N
o
4
10
29
–6
1
12
0
12
10
0
n.
a.
Er
do
ga
na
20
15
Pr
os
H
bA
1c
	=
	6
.1
–7
.5
,	
Ty
pe
 2
 
>1
2
12
52
.6
22
0
22
10
0
n.
a.
N
o
>1
2
12
49
.5
21
0
21
10
0
n.
a.
Es
ko
w
a
20
17
O
bs
er
va
tio
na
l
H
bA
1c
 6
–7
.9
, T
yp
e 
2
24
9
59
.9
21
0
21
10
0
n.
a.
H
bA
1c
	≥
	8
.0
,	T
yp
e	
2
24
11
59
.9
38
2
36
94
.7
4
n.
r.
O
at
es
a
20
14
C
oh
or
t (
Pr
os
)
H
bA
1c
	≤
	5
.9
,	T
yp
e	
2
12
50
64
10
0
1
99
99
n.
r.
H
bA
1c
 =
 6
.0
–8
.0
, 
Ty
pe
 2
12
47
64
94
1
93
98
.9
n.
r.
H
bA
1c
	≥
	8
.1
,	T
yp
e	
2
12
20
64
40
0
40
10
0
n.
a.
Pe
le
d
20
03
C
S
Ty
pe
 2
 d
ia
be
te
s
60
41
n.
r.
14
1
8
13
3
94
.3
3
Ea
rly
: 6
; 
La
te
: 2
N
ot
e.
 n
: n
um
be
r; 
n.
a.
: n
ot
 a
pp
lic
ab
le
; P
ro
s:
 p
ro
sp
ec
tiv
e 
st
ud
y;
 n
.r.
: n
ot
 re
po
rt
ed
; R
et
ro
: r
et
ro
sp
ec
tiv
e 
st
ud
y;
 C
S:
 c
as
e 
se
rie
s;
 E
ar
ly
: b
ef
or
e 
im
pl
an
t 
lo
ad
in
g;
 L
at
e:
 a
ft
er
 im
pl
an
t l
oa
di
ng
; S
R:
 c
al
cu
la
te
d 
su
rv
iv
al
 ra
te
.
a D
iff
er
en
t s
tu
dy
 g
ro
up
s 
w
ith
in
 th
e 
sa
m
e 
st
ud
y 
re
po
rt
ed
 in
 s
ep
ar
at
e 
ro
w
s.
     |  323SCHIMMEL Et aL.
Although ranking among the most common diseases in geriat‐
ric patients, there is no evidence on implant dentistry on condi‐
tions including cirrhosis of the liver, osteoarthritis, or respiratory 
diseases and sparse knowledge on patients with neurocognitive 
impairment and their respective treatments. This may constitute 
a potential risk for implant surgery, osseointegration and implant 
survival; for example, the use of glucocorticoids might induce os‐
teoporosis and thus, influence bone healing (Krennmair, Seemann 
& Piehslinger, 2010). With multiple chronic conditions present, 
their effect on implant treatment becomes complex and poorly 
understood.
4.1.1 | Cardiovascular disease
The main concern in patients with CVD may be related to the general 
risk in performing invasive surgery because of prescribed anticoagu‐
lants or changes in blood pressure due to vasoconstrictor containing 
local anaesthetics.
Interestingly, the current review identified one study that re‐
ported the positive impact of antihypertensive drugs on implant 
survival (Wu et al., 2016). The authors hypothesize that this may be 
related to the positive effect of such drugs including beta‐blockers, 
thiazide diuretics, ACE inhibitors, and ARBs on bone metabolism, 
which constitutes an interesting field for further research.
4.1.2 | Radiotherapy
The use of head and neck radiotherapy has been associated with a 
reduced survival rate of implants. In many cases, implants may be 
the only possibility of a prosthetic restoration, aiming for the pa‐
tient’s functional rehabilitation, social reintegration and psycho‐
logical	 well‐being	 (Müller,	 Schadler,	Wahlmann	 &	 Newton,	 2004).	
A recent review suggests that recently improved protocols of ad‐
ministering therapeutic radiation doses carry less risk for implant 
failure and MRONJ, compared to traditional protocols (Schiegnitz, 
Al‐Nawas, Kammerer & Grotz, 2014).
4.1.3 | Antiresorptive therapy and osteoporosis
Antiresorptive therapy with agents that have long‐lasting effects on 
bone metabolism can also be a major obstacle for implant surgery. 
Patients with Cancer with bone metastases (e.g., from breast or 
prostate cancer) or with multiple myeloma often receive high‐dose 
intravenous ART. Dental implant treatment is often contraindicated 
in these patients because of the strongly increased risk of MRONJ 
(Lazarovici et al., 2010).
Osteoporosis patients, on the other hand, receive ART at much 
lower doses. As their risk of MRONJ is much lower, implants are in‐
creasingly utilized in these patients (Chadha, Ahmadieh, Kumar & 
Sedghizadeh, 2013). The risk of MRONJ in osteoporosis patients on 
low‐dose bisphosphonates is estimated to be 0.7 per 100,000 per‐
son‐years of exposure, and fewer than 100 cases of MRONJ after T
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F I G U R E  1   The search flow diagram, for the systematic literature search and selection process according to the PRISMA guidelines (n, 
number of articles; κ, Kappa statistics for interinvestigator agreement; R#1, reviewer 1; R#2, Reviewer 2; *, search results for studies with 
elderly	cohort	aged	≥75	years	AND	dental	implants	AND	common	medical	conditions;	§,	search	results	for	studies	with	elderly	cohort	aged	
≥75	years	AND	dental	implants	without	common	medical	conditions;	†,	search	results	for	studies	with	cohort	with	dental	implants	AND	
common	medical	conditions	without	the	age	(≥75	years)	filter]	
F I G U R E  2   Forest plot showing the 1‐year postloading implant survival rate (CI, confidence interval)
F I G U R E  3  Forest	plot	showing	the	5‐year	postloading	implant	survival	rate	(CI,	confidence	interval)
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implant therapy in this group of patients have been reported (Ata‐
Ali, Ata‐Ali, Penarrocha‐Oltra & Galindo‐Moreno, 2014).
Until now, there is no evidence that the intravenous low‐dose ad‐
ministration carries a greater risk of MRONJ than oral medication, but 
precautions should be taken when planning and performing implant 
surgery (Schimmel et al., 2017). Moderate level evidence suggests 
that patients suffering from osteoporosis have a higher incidence of 
tooth loss (Anil, Preethanath, AlMoharib, Kamath & Anand, 2013). 
This may be related to a higher level of osteoclastic activity and a less 
dense bony structure, favoring progress of periodontal bone resorp‐
tion in response to gingival inflammation (Wang & McCauley, 2016).
4.1.4 | Hyposalivation
Hyposalivation is very frequent among geriatric patients, not only 
as a consequence of radiotherapy, but mainly as a consequence of 
polypharmacy. However, no study dealt directly with the influence 
of this condition on the survival, not to mention success, of implants 
and implant prosthesis, which constitutes a major knowledge gap in 
gero‐implantology.
There are, however, studies that have investigated the influence 
of Sjögren’s syndrome on implant survival. A very recent compar‐
ative study from Korfage et al. (2016) indicated that the condition 
may be related to a higher risk of early implant failure.
4.1.5 | Diabetes
Type 2 diabetes signifies the body’s resistance and inability to pro‐
duce adequate amounts of insulin. It is the most common form of the 
disease in geriatric patients. Among other symptoms, Type 2 diabet‐
ics can experience microvascular and vascular damage as well as an 
impaired wound healing. Patients are more susceptible to periodon‐
titis and tooth loss (Persson, 2017). The main marker of glycemic 
control in diabetic patients is hemoglobin A1C (HbA1c), and numerous 
studies identified in this review demonstrate that HbA1c levels above 
8% may result in reduced implant survival compared to lower levels.
4.2 | Strengths and weaknesses of the review
Prospective clinical studies on implants placed in geriatric patients 
are scarce. This may be due to a series of logistical challenges where 
older patients would require examination and treatment in their own 
home or a residential institution. In addition, older patient cohorts 
are	extremely	heterogeneous,	as	“not	all	old	are	old”	(Bürger,	1960).	
The discrepancy between the biological and the numerical age can 
expand dramatically in advanced age, as the long‐term effects of nu‐
trition, lifestyle choices, socioeconomic status, and disease experi‐
ence accumulate over a lifetime.
The search for eligible studies for this systematic review was lim‐
ited by the fact that a large body of evidence published in the 1980s 
and 1990s from prospective geriatric studies studied implants with 
turned/machined titanium surfaces. These surfaces are not relevant 
in daily practice anymore; hence these studies were excluded from 
this review. Further weakness arises from the use of filters in our 
search that might have inadvertently omitted some relevant articles. 
The search truncations were not elaborately used for more search 
terms in “all fields,” hence, this could have further limited the search 
yield. Furthermore, the search process of this review did not include 
conference proceedings. As the focus of this systematic review was 
not only on age, but also on comorbidity, a general lack of reporting 
on the medical status of study participants was noted in many pa‐
pers, which further reduced the available evidence for highlighting 
the effect of the most common chronic conditions and their treat‐
ment in elderly patients.
Initially, a further exclusion criterion for this systematic search 
was a minimum sample of 10 participants for each included study. 
During the abstract screening, it became obvious that many stud‐
ies would therefore have to be excluded. Relevant evidence would 
remain unreported in this review, for example, in relation to neu‐
rocognitive impairment where evidence is extremely scarce. It was, 
therefore, decided to remove this exclusion criterion post hoc. 
However, for the meta‐analyses, studies reporting on single cases 
or case series with less than 10 cases were still excluded, as Stewart 
F I G U R E  4  Funnel	plot	of	the	included	prospective	studies	in	the	1‐year	(a)	and	in	the	5‐year	(b)	analyses	showing	no	publication	bias
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et	al.	(2015)	proposed	in	the	CONSORT‐IPD	statement	the	inclusion	
of IPD would require a different approach.
Unfortunately, patient‐reported outcome measures are not in‐
cluded in the analysis for this systematic review due to underreport‐
ing of the factors in most implant studies.
The strength of this review is the limitation of the participants 
included	to	those	aged	of	75	years	and	older.	Previous	reviews	exist	
on the use of implants in medical compromised patients (Beikler & 
Flemmig,	2003;	Bornstein	et	al.,	2009,	2015),	but	none	have	previ‐
ously focused on the impact of health status in combination with 
aging and frailty. Despite a comprehensive, meticulous, and sys‐
tematic search, this review did not identify any studies on implant 
survival in relation to medical conditions in purely geriatric patients. 
Hence, this review too was not able to investigate the combined ef‐
fect of age and chronic disease, and it was post hoc decided to re‐
port on any‐age implant survival rates in the most common geriatric 
medical conditions. Yet, knowledge on the interactions of old age, 
medical conditions, and implant survival or even success would be 
essential for clinical decision‐making and meticulous reporting on 
medical conditions in elder study participants should be encouraged 
for future studies on implant survival.
Although this review did not reveal age as a risk factor for os‐
seointegration, immunosenescence can potentially compromise the 
body’s defense mechanisms where the bacterial load around im‐
plants challenges the health of the peri‐implant mucosa. The term 
immunosenescence refers to the aging of the immune system. It was 
suggested that the human immune system declines in effectiveness 
with age (Preshaw, Henne, Taylor, Valentine & Conrads, 2017). This 
can be a significant issue for functionally impaired older patients 
when oral hygiene is neglected (Meyer et al., 2017).
A further factor to be considered is that the implants in patients 
lost to follow‐up were excluded from the survival analysis. However, 
reporting on the uncensored survival rates could have possibly over‐
whelmed the results in a negative direction, providing an unrealisti‐
cally negative picture. Dropout rates are high in geriatric studies, due 
to the high prevalence of medical conditions, functional impairment, 
and death. The bias introduced using censored data (the “unknown”) 
on potential knowledge gain, might be more important in geriatric 
studies than elsewhere in the literature.
4.3 | Clinical relevance of the findings of this 
systematic review
A particularly pertinent aspect of this review is the clinical rele‐
vance of the survival rate of implants in view of the patient’s life 
expectancy and morbidity. For patients affected with head and 
neck cancer, implants may be the only means to achieve a psycho‐
social	and	functional	rehabilitation	(Müller	et	al.,	2004).	Given	the	
undoubted benefits of an implant retained restoration compared to 
removable alternatives for oncology patients, the use of implants 
may even be justified when implant survival rates are significantly 
below those reported for healthy patients. A similar viewpoint may 
apply to patients with hyposalivation, as wearing a conventional 
denture may be almost impossible due to a lack of retention and 
pain caused by the intaglio surface rubbing on the dry and sensitive 
mucosa. Again, clinical decision‐making must not only be based on 
the survival rate, but rather on the patient’s subjective gain in qual‐
ity of life, comfort, and overall well‐being which should outweigh 
the associated risks. This review provides a valuable insight into 
the survival rates of implants which are vitally important to advise 
patients as part of the consent procedure prior to undertaking any 
intervention.
However, it should be noted that in elderly patients, implant 
success is rarely assessed in a relevant manner. An implant may be 
perfectly osseointegrated, but a patient with complex implant pros‐
theses who is dependent on help for the activities of daily living may 
not wear or clean it anymore, because the management is too com‐
plex. This cannot be considered a successful treatment in this patient 
population	(Müller	&	Schimmel,	2016).
4.4 | Implications for research
Substantial underreporting was noted on several important medical 
conditions in geriatric patients, which may have an impact on implant 
survival. Future, high‐quality research is needed with comprehen‐
sive recording of study participants’ medical conditions, and stand‐
ard protocols for reporting these comorbidities should be defined 
based on the outcome of this systematic review.
The current review reveals an important knowledge gap when it 
comes to implant therapy in elderly and geriatric patients. For some of 
the most common geriatric medical conditions such as cancer and dia‐
betes, there is evidence available in relation to implant surgery and im‐
plant prostheses—however, almost exclusively from younger patient 
groups. This limits the relevance of the findings for geriatric patients, 
who often take multiple medications and present with immunosenes‐
cence (Lopez‐Otin, Blasco, Partridge, Serrano & Kroemer, 2013) or de‐
layed wound healing due to qualitative or quantitative protein‐energy 
malnutrition	(Schimmel,	Katsoulis,	Genton	&	Müller,	2015).
5  | CONCLUSIONS
The provision of implant‐supported/retained prostheses in geriatric 
subjects is a predictable treatment option with a high rate of implant 
survival. The functional and psychosocial benefits of an implant res‐
toration should outweigh the reported relative risks associated with 
common medical conditions and their respective treatments.
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